Table 2 Additional characteristics among COVID-19 cancer patients with respiratory failure. (n = 65)
| Â | n (%) |
|---|---|
Cancer site | Â |
 Hematological | 8 (12.3) |
  Lymphoma | 7(10.8) |
  Myeloproliferative neoplasm | 1(1.5) |
 Solid tumors | 57 (87.7) |
  Breast | 4(6.2) |
  Prostate | 5(7.7) |
  Gastrointestinal | 10(15.4) |
  Hepatocellular carcinoma | 4(6.2) |
  Biliary tract | 1(1.5) |
  Pancreas | 1(1.5) |
  Lung | 16(24.6) |
  Gynecological | 4(6.2) |
  Head and neck | 3(4.6) |
  Genitourinary | 5(7.7) |
  Musculoskeletal | 1(1.5) |
  Central nervous system | 2(3.1) |
  Malignancy of unknown origin | 1(1.5) |
Cancer treatment within 4 weeks of COVID-19 diagnosis | 34 (52.3) |
 ICI* combination | 4 (6.2) |
  ICI + chemotherapy | 3 (4.6) |
  ICI + TKI* | 1(1.5) |
 Cytotoxic chemotherapy | 16 (24.6) |
  Intravenous chemotherapy | 12 (18.5) |
  Oral chemotherapy | 4 (6.2) |
 Endocrine therapy | 1 (1.5) |
 TKI | 9 (13.8) |
 Monoclonal antibody | 3 (4.6) |
 Anti-VEGF* agents | 1 (1.5) |